Aquestive Therapeutics price target lowered to $6 from $8 at Lake Street

Core Viewpoint - Lake Street has lowered the price target for Aquestive Therapeutics (AQST) to $6 from $8 while maintaining a Buy rating after the company received a Complete Response Letter (CRL) for Anaphylm and plans to resubmit in Q3 [1] Group 1 - The price target adjustment reflects the delay in the approval of Anaphylm [1] - Revenue estimates have been adjusted accordingly due to the CRL received by the company [1]